Skip to main content

Table 1 Baseline imaging characteristics

From: Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis

Variable

Secukinumab 150 mg with loading (n = 185)

Secukinumab 150 mg without loading (n = 184)

Secukinumab pooled (n = 369)

Placebo (n = 186)

Radiographs

 Total sacroiliitis score, mean (SD) (range, 0–8)

1.40 (1.47)

1.44 (1.50)

1.42 (1.48)

1.51 (1.58)

 mSASSS score, mean (SD) (range, 0–72)

0.80 (2.70)

0.75 (2.59)

0.77 (2.64)

0.84 (2.43)

 Patients with syndesmophytes, n (%)

29 (15.7)

33 (17.9)

62 (16.8)

27 (14.7)

MRI

 SI joint bone marrow edema score, mean (SD) (0–24)

2.14 (3.52)

1.94 (3.39)

2.04 (3.45)

2.26 (3.69)

 Spinal inflammation, Berlin score, mean (SD) (0–69)

0.78 (1.70)

0.86 (1.81)

0.82 (1.75)

1.07 (2.28)

  1. All patients with baseline assessments are included
  2. MRI magnetic resonance imaging, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, SD standard deviation, SI sacroiliac